The past year saw record valuations, innovative financing tools, and rigorous healthcare and life sciences innovation in the face of the evolving COVID-19 pandemic. Moving into 2022, investors are keeping an eye on the legislative horizon to see if Congress will act to make telehealth waivers permanent, and are preparing for another wave of potential market challenges as new variants emerge. Adaptability remains key for investors and target companies alike.
Here, our health private equity team explores the trends that shaped the sector in 2021 and looks ahead to the issues that may influence markets and drive deals in 2022.
